{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:17:58Z","timestamp":1791530278294,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for the two-dose Ebola vaccine regimen Ad26.ZEBOV, MVA-BN-Filo. Ebola virus (EBOV) glycoprotein binding antibody data obtained from 764 vaccinated healthy adults in five clinical studies (NCT02416453, NCT02564523, NCT02509494, NCT02543567, NCT02543268) were used to calculate mean predicted survival probability (with preplanned 95% confidence interval [CI]). We used a logistic regression model based on EBOV glycoprotein binding antibody responses in vaccinated non-human primates (NHPs) and NHP survival after EBOV challenge. While the protective effect of the vaccine regimen in humans can be inferred in this fashion, the extrapolated survival probability cannot be directly translated into vaccine efficacy. The primary immunobridging analysis evaluated the lower limit of the CI against predefined success criterion of 20% and passed with mean predicted survival probability of 53.4% (95% CI: 36.7\u201367.4).<\/jats:p>","DOI":"10.1038\/s41541-022-00564-z","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:11:36Z","timestamp":1669835496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola"],"prefix":"10.1038","volume":"7","author":[{"given":"Viki","family":"Bockstal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Leyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Heerwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Spiessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen N.","family":"Stoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-4801","authenticated-orcid":false,"given":"Ramon","family":"Roozendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Van Effelterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auguste","family":"Gaddah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet A.","family":"Van Roey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Solforosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-6231","authenticated-orcid":false,"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-1294","authenticated-orcid":false,"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-5729","authenticated-orcid":false,"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-2266","authenticated-orcid":false,"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Van Hoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"564_CR1","first-page":"270","volume":"56","author":"WHO\/International Study Team.","year":"1978","unstructured":"WHO\/International Study Team. Ebola haemorrhagic fever in Sudan, 1976. Bull. World Health Organ 56, 270 (1978).","journal-title":"Bull. World Health Organ"},{"key":"564_CR2","unstructured":"Centers for Disease Control and Prevention. 2014\u20132016 Ebola outbreak in West Africa. https:\/\/www.cdc.gov\/vhf\/ebola\/history\/2014-2016-outbreak\/index.html (2019)."},{"key":"564_CR3","unstructured":"World Health Organization. 10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue. https:\/\/www.who.int\/news\/item\/25-06-2020-10th-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-over-vigilance-against-flare-ups-and-support-for-survivors-must-continue (2020)."},{"key":"564_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"564_CR5","unstructured":"World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. https:\/\/www.who.int\/publications\/m\/item\/preliminary-results-on-the-efficacy-of-rvsv-zebov-gp-ebola-vaccine-using-the-strategy-in-the-control-of-an-ebola-outbreak (2019)."},{"key":"564_CR6","unstructured":"World Health Organization. Strategic Advisory Group of Experts (SAGE) on immunization interim recommendations on vaccination against Ebola virus disease (EVD). https:\/\/www.who.int\/immunization\/policy\/position_papers\/interim_ebola_recommendations_may_2019.pdf (2019)."},{"key":"564_CR7","unstructured":"Rwanda Biomedical Centre. The Ministry of Health launched UMURINZI Ebola vaccine program campaign. https:\/\/rbc.gov.rw\/index.php?id=100&tx_news_pi1%5Bnews%5D=530&tx_news_pi1%5Bday%5D=14&tx_news_pi1%5Bmonth%5D=12&tx_news_pi1%5Byear%5D=2019&cHash=9bcec711608382d977905e5f68b0e56a (2019)."},{"key":"564_CR8","unstructured":"European Medicines Agency. Zabdeno. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zabdeno (2020)."},{"key":"564_CR9","unstructured":"European Medicines Agency. Mvabea. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvabea (2020)."},{"key":"564_CR10","unstructured":"U.S. Food and Drug Administration. Product development under the animal rule: guidance for industry. https:\/\/www.fda.gov\/files\/drugs\/published\/Product-Development-Under-the-Animal-Rule.pdf (2015)."},{"key":"564_CR11","unstructured":"European Medicines Agency. Conditional marketing authorisation. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/conditional-marketing-authorisation (2004)."},{"key":"564_CR12","unstructured":"European Medicines Agency. Guideline on procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to Article 14 (8) of regulation (EC) no. 726\/2004. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-procedures-granting-marketing-authorisation-under-exceptional-circumstances-pursuant\/2004_en.pdf (2005)."},{"key":"564_CR13","first-page":"253","volume":"67","author":"MC St Claire","year":"2017","unstructured":"St Claire, M. C., Ragland, D. R., Bollinger, L. & Jahrling, P. B. Animal models of ebolavirus infection. Comp. Med. 67, 253\u2013262 (2017).","journal-title":"Comp. Med."},{"key":"564_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.24272\/j.issn.2095-8137.2017.053","volume":"39","author":"V Siragam","year":"2018","unstructured":"Siragam, V., Wong, G. & Qiu, X. G. Animal models for filovirus infections. Zool. Res 39, 15\u201324 (2018).","journal-title":"Zool. Res"},{"key":"564_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0524-z","volume":"13","author":"M Ajelli","year":"2015","unstructured":"Ajelli, M. et al. The 2014 Ebola virus disease outbreak in Pujehun, Sierra Leone: epidemiology and impact of interventions. BMC Med 13, 281 (2015).","journal-title":"BMC Med"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1086\/514308","volume":"179(Suppl 1)","author":"MA Bwaka","year":"1999","unstructured":"Bwaka, M. A. et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 179(Suppl 1), S1\u2013S7 (1999).","journal-title":"J. Infect. Dis."},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/infdis\/jiv304","volume":"212","author":"G Fitzpatrick","year":"2015","unstructured":"Fitzpatrick, G. et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014. J. Infect. Dis. 212, 1752\u20131758 (2015).","journal-title":"J. Infect. Dis."},{"key":"564_CR18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/S1473-3099(15)00144-9","volume":"15","author":"L Hunt","year":"2015","unstructured":"Hunt, L. et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 15, 1292\u20131299 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1086\/514306","volume":"179(Suppl 1)","author":"AS Khan","year":"1999","unstructured":"Khan, A. S. et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 179(Suppl 1), S76\u2013S86 (1999).","journal-title":"J. Infect. Dis."},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1086\/514297","volume":"179(Suppl 1)","author":"R Ndambi","year":"1999","unstructured":"Ndambi, R. et al. Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179(Suppl 1), S8\u2013S10 (1999).","journal-title":"J. Infect. Dis."},{"key":"564_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2015.19","volume":"2","author":"MD Van Kerkhove","year":"2015","unstructured":"Van Kerkhove, M. D., Bento, A. I., Mills, H. L., Ferguson, N. M. & Donnelly, C. A. A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making. Sci. Data 2, 150019 (2015).","journal-title":"Sci. Data"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ajic.2016.04.216","volume":"44","author":"Z Xu","year":"2016","unstructured":"Xu, Z. et al. Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone. Am. J. Infect. Control 44, 1285\u20131290 (2016).","journal-title":"Am. J. Infect. Control"},{"key":"564_CR23","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s10096-015-2457-z","volume":"34","author":"T Yan","year":"2015","unstructured":"Yan, T. et al. Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak. Eur. J. Clin. Microbiol Infect. Dis. 34, 2089\u20132095 (2015).","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"564_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00261-9","volume":"5","author":"R Roozendaal","year":"2020","unstructured":"Roozendaal, R. et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. npj Vaccines 5, 112 (2020).","journal-title":"npj Vaccines"},{"key":"564_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrmicro2129","volume":"7","author":"NJ Sullivan","year":"2009","unstructured":"Sullivan, N. J., Martin, J. E., Graham, B. S. & Nabel, G. J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol 7, 393\u2013400 (2009).","journal-title":"Nat. Rev. Microbiol"},{"key":"564_CR26","doi-asserted-by":"publisher","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","volume":"4","author":"G Wong","year":"2012","unstructured":"Wong, G. et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med 4, 158ra146 (2012).","journal-title":"Sci. Transl. Med"},{"key":"564_CR27","unstructured":"Janssen Vaccines & Prevention B.V. A study to assess safety, tolerability, and immunogenicity of three heterologus 2-dose regimens of the candidate prophylactic vaccines for Ebola in healthy adults. ClinicalTrials.gov. NCT02416453. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02416453 (2021)."},{"key":"564_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 21, 493\u2013506 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"564_CR29","unstructured":"Janssen Vaccines & Prevention B.V. Safety, tolerability and immunogenicity study of 3 prime-boost regimens for Ebola vaccines Ad26.ZEBOV\/MVA-BN-Filo in healthy adults, children and human immunodeficiency virus positive (HIV+) adults. ClinicalTrials.gov. NCT02564523. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02564523 (2022)"},{"key":"564_CR30","doi-asserted-by":"publisher","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","volume":"18","author":"H Barry","year":"2021","unstructured":"Barry, H. et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa. PLoS Med 18, e1003813 (2021).","journal-title":"PLoS Med"},{"key":"564_CR31","doi-asserted-by":"publisher","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","volume":"19","author":"Z Anywaine","year":"2022","unstructured":"Anywaine, Z. et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trial. PLoS Med 19, e1003865 (2022).","journal-title":"PLoS Med"},{"key":"564_CR32","unstructured":"Janssen Vaccines & Prevention B.V. Staged phase 3 study to assess the safety and immunogenicity of Ebola candidate vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone). ClinicalTrials.gov. NCT02509494. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02509494 (2022)."},{"key":"564_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","volume":"22","author":"D Ishola","year":"2022","unstructured":"Ishola, D. et al. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect. Dis. 22, 97\u2013109 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"564_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","volume":"22","author":"MO Afolabi","year":"2022","unstructured":"Afolabi, M. O. et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect. Dis. 22, 110\u2013122 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"564_CR35","unstructured":"Janssen Vaccines & Prevention B.V. A study to evaluate a range of dose levels of Ad26.ZEBOV and MVA-BN-Filo in healthy adult participants. ClinicalTrials.gov. NCT02543567. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02543567 (2017)."},{"key":"564_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41541-021-00402-8","volume":"6","author":"V Bockstal","year":"2021","unstructured":"Bockstal, V. et al. Assessments of different batches and dose levels of a heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen: two phase 3, randomized, placebo-controlled studies. npj Vaccines 6, 157 (2021).","journal-title":"npj Vaccines"},{"key":"564_CR37","unstructured":"Crucell Holland BV. A study to evaluate the immunogenicity, safety and tolerability of Ad26.ZEBOV and MVA-BN-Filo in healthy adult participants. ClinicalTrials.gov. NCT02543268. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02543268 (2016)."},{"key":"564_CR38","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D. et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315, 1610\u20131623 (2016).","journal-title":"JAMA"},{"key":"564_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/infdis\/jiz071","volume":"220","author":"G Mutua","year":"2019","unstructured":"Mutua, G. et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J. Infect. Dis. 220, 57\u201367 (2019).","journal-title":"J. Infect. Dis."},{"key":"564_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/infdis\/jiz070","volume":"220","author":"Z Anywaine","year":"2019","unstructured":"Anywaine, Z. et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J. Infect. Dis. 220, 46\u201356 (2019).","journal-title":"J. Infect. Dis."},{"key":"564_CR41","unstructured":"European Medicines Agency. Assessment report: Dengvaxia. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/dengvaxia-epar-public-assessment-report_en.pdf (2018)."},{"key":"564_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-publhealth-032315-021507","volume":"37","author":"R Strasser","year":"2016","unstructured":"Strasser, R., Kam, S. M. & Regalado, S. M. Rural health care access and policy in developing countries. Annu Rev. Public Health 37, 395\u2013412 (2016).","journal-title":"Annu Rev. Public Health"},{"key":"564_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.it.2014.07.003","volume":"35","author":"Y Valdez","year":"2014","unstructured":"Valdez, Y., Brown, E. M. & Finlay, B. B. Influence of the microbiota on vaccine effectiveness. Trends Immunol. 35, 526\u2013537 (2014).","journal-title":"Trends Immunol."},{"key":"564_CR44","doi-asserted-by":"crossref","unstructured":"Mentzer, A. J., O\u2019Connor, D., Pollard, A. J. & Hill, A. V. Searching for the human genetic factors standing in the way of universally effective vaccines. Philos. Trans. R Soc. Lond. B Biol. Sci. 370, 20140341 (2015).","DOI":"10.1098\/rstb.2014.0341"},{"key":"564_CR45","doi-asserted-by":"publisher","first-page":"e0230406","DOI":"10.1371\/journal.pone.0230406","volume":"15","author":"R Potluri","year":"2020","unstructured":"Potluri, R. et al. Impact of prophylactic vaccination strategies on Ebola virus transmission: a modeling analysis. PLoS One 15, e0230406 (2020).","journal-title":"PLoS One"},{"key":"564_CR46","doi-asserted-by":"publisher","first-page":"151ra126","DOI":"10.1126\/scitranslmed.3004073","volume":"4","author":"MP Fay","year":"2012","unstructured":"Fay, M. P. et al. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci. Transl. Med 4, 151ra126 (2012).","journal-title":"Sci. Transl. Med"},{"key":"564_CR47","unstructured":"GAVI, the Vaccine Alliance. 10 infectious diseases that could be the next pandemic. https:\/\/www.gavi.org\/vaccineswork\/10-infectious-diseases-could-be-next-pandemic (2020)."},{"key":"564_CR48","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/v6072673","volume":"6","author":"R Hirschberg","year":"2014","unstructured":"Hirschberg, R. et al. Challenges, progress, and opportunities: proceedings of the Filovirus Medical Countermeasures Workshop. Viruses 6, 2673\u20132697 (2014).","journal-title":"Viruses"},{"key":"564_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27\u201338 (1993).","journal-title":"Biometrika"},{"key":"564_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jviromet.2018.02.018","volume":"255","author":"J Logue","year":"2018","unstructured":"Logue, J. et al. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J. Virol. Methods 255, 84\u201390 (2018).","journal-title":"J. Virol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00564-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:16:45Z","timestamp":1669835805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00564-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00564-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Janssen had a role in the conception or design of the work, acquisition of the data, analysis or interpretation of the data, preparation of the manuscript, and decision to publish. All authors were full-time employees of Janssen Pharmaceutical Companies of Johnson & Johnson at the time of the study and may own shares in Janssen Pharmaceutical Companies of Johnson & Johnson. Dr Van Effelterre reports ownership of shares in GlaxoSmithKline. All authors also report receiving grant support, paid to their institution, from the following: Biomedical Advanced Research and Development Authority (BARDA; Contract: HHSO100201700013C); the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH; Contracts: HHSN272200800056C, HHSN272201000006I, and HHSN272201200003I); and the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115854 [EBOVAC1]). Additionally, this project has received funding from the Innovative Medicines Initiative 2 () Joint Undertaking under EBOVAC2 grant agreement No 115861; this Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Association (EFPIA). Dr Callendret is listed as an inventor on an international patent application (number PCT\/US2015\/048357) with publication number WO 2016\/036955, entitled \u201cMethods and compositions for inducing protective immunity against filovirus infection.\u201d Dr Solforosi has participated in advisory boards for Abilita Bio, Inc. No other disclosures are reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}